<DOC>
	<DOCNO>NCT00742716</DOCNO>
	<brief_summary>This study investigate level CTA018 body time ( pharmacokinetics , PK ) patient chronic kidney disease ( CKD ) secondary hyperparathyroidism ( SHPT ) , undergo regular hemodialysis . This study also investigate safety effect different strength CTA018 , parathyroid hormone ( PTH ) level .</brief_summary>
	<brief_title>Safety Study CTA018 Injection Treat Stage 5 Chronic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<criteria>Body mass index 18 35 On maintenance hemodialysis three time per week Serum iPTH value great equal 300 pg/mL lower equal 1000 pg/mL Adjusted total serum calcium value great equal 8.4 mg/dL low 10.0 mg/dL Serum phosphorus value great equal 2.5 mg/dL low equal 5.5 mg/dL Serum 25hydroxyvitamin D level great equal 15 ng/mL Willing able discontinue vitamin D and/or bone metabolism therapy least 2 week prior administration Study Drug , length study On bisphosphonates least three month prior first dose Study Drug Currently take cytochrome P450 3A inhibitor and/or inducer Abnormal liver function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Parathyroid Diseases</keyword>
	<keyword>Renal Insufficiency</keyword>
	<keyword>Kidney Failure , Chronic</keyword>
	<keyword>Hyperparathyroidism , Secondary</keyword>
	<keyword>Vitamin D</keyword>
	<keyword>Hyperparathyroidism</keyword>
	<keyword>Renal Insufficiency , Chronic</keyword>
	<keyword>Kidney Diseases</keyword>
	<keyword>Kidney Failure</keyword>
</DOC>